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Abstract
Background: Elevated serum levels of luteinizing hormone and slightly decreased serum levels of testosterone
(mild Leydig cell insufficiency) is a common hormonal disturbance in testicular cancer (TC) survivors. A number of
studies have shown that low serum levels of testosterone is associated with low grade inflammation and increased
risk of metabolic syndrome. However, so far, no studies have evaluated whether testosterone substitution improves
metabolic dysfunction in TC survivors with mild Leydig cell insufficiency.
Methods/design: This is a single-center, randomized, double-blind, placebo-controlled study, designed to evaluate
the effect of testosterone replacement therapy in TC survivors with mild Leydig cell insufficiency. Seventy subjects
will be randomized to receive either testosterone replacement therapy or placebo. The subjects will be invited for
an information meeting where informed consent will be obtained. Afterwards, a 52-weeks treatment period begins
in which study participants will receive a daily dose of transdermal testosterone or placebo. Dose adjustment will
be made three times during the initial 8 weeks of the study to a maximal daily dose of 40 mg of testosterone in
the intervention arm. Evaluation of primary and secondary endpoints will be performed at baseline, 26 weeks
post-randomization, at the end of treatment (52 weeks) and 3 months after completion of treatment (week 64).
Discussion: This study is the first to investigate the effect of testosterone substitution in testicular cancer survivors
with mild Leydig cell insufficiency. If positive, it may change the clinical handling of testicular cancer survivors with
borderline low levels of testosterone.
Trial registration: ClinicalTrials.gov: NCT02991209 (November 25, 2016).
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Background
Testicular cancer (TC) is the most common solid
tumour in men between 18 and 35 years of age in
developed countries [1], and more than 95% of pa-
tients become long-term survivors [2]. In conse-
quence, a wide range of studies have investigated the
prevalence of late effects to TC treatment such as
hormonal disturbances [3–5], cardiovascular disease
[6–8] and metabolic syndrome [9–12]. The risk of
cardiovascular disease is increased in TC patients
treated with cisplatin-based chemotherapy when
compared to the background population, and it has
uniformly been reported that low serum levels of
testosterone are associated with increased risk of
metabolic syndrome. This has led to the hypothesis
that decreased serum levels of testosterone in cancer
survivors increase the risk of insulin resistance, meta-
bolic syndrome and long-term risk of cardiovascular
disease [13]. Subjective symptoms of testosterone defi-
ciency are decreased libido, decreased level of energy,
depressive symptoms, impaired cognitive function and
decreased muscle strength while objective signs are
decreased bone density, decreased lean body mass,
abdominal obesity and anemia [14, 15]. It is well
documented that testosterone replacement therapy
improves these conditions in patients with manifest
testosterone deficiency [16, 17] and numerous studies
have demonstrated increased insulin sensitivity, de-
creased systemic inflammation and recovery of com-
ponents of the metabolic syndrome [18–20]. However,
a substantial proportion of TC survivors are in a
compensated state with elevated luteinizing hormone
(LH)-levels in combination with borderline low levels
of testosterone (mild Leydig cell insufficiency) [21]. To
our knowledge, only one study has examined the
effects of testosterone replacement therapy in mild
Leydig cell insufficiency [22]. This randomized,
placebo-controlled study investigated the effect of
12 months of testosterone replacement therapy in 30
long-term survivors of haematological cancer and
found a reduction of fatigue and a slight decrease in
low density lipoprotein (LDL) cholesterol, and con-
cluded that testosterone substitution should not be
recommended in this condition. However, the limit
for testosterone replacement therapy was total testos-
terone <20 mmol/L and LH > 8 IU/L and the effect
on fasting blood glucose, insulin sensitivity and meta-
bolic syndrome was not evaluated.
Thus, the purpose of the present study is to deter-
mine whether testosterone replacement therapy im-
proves insulin sensitivity and thus potentially reduces
the long-term risk of cardiovascular disease in TC




Seventy TC survivors with no relapse >1 year since treat-
ment will be included in the study. The main inclusion
criteria are serum levels of LH > 2 standard devia-
tions (SD) above the age-adjusted mean value and
serum levels of free testosterone between 2 SD below
the age-adjusted mean value and the age-adjusted
mean value. Further inclusion and exclusion criteria
are presented in Table 1.
Recruitment and informed consent
The study flow is presented in Fig. 1. Potential study
subjects will be recruited by clinicians during 5-years
follow-up after treatment for TC at the outpatient
clinic of Department of Clinical Oncology at
Copenhagen University Hospital, Rigshospitalet. Inter-
ested patients will be contacted by the study coordin-
ator, who will provide oral and written information
about the study. An informed consent form will be
signed, when there is a mutual understanding that the
subject has understood the information given and still
wants to participate. Afterwards, an appointment for
screening will be made.
Randomization and procedures for breakage of
randomization code
The 70 study participants will be randomized 1:1 to
active treatment or placebo. Randomization will be done
Table 1 Eligibility Criteria
Inclusion criteria
- Age > 18 years and <65 years
- Previous treatment for testicular cancer
- No signs of relapse 1 year after the last treatment (orchiectomy,
radiotherapy, chemotherapy)
- Serum free testosterone < the age-adjusted mean value and >2
standard deviations (SD) below the age-adjusted mean value
- Serum luteinizing hormone (LH) > 2 SD above the age-adjusted
mean value
Exclusion criteria
- Testosterone treatment within the last 6 months
- Contraindications to testosterone treatment: (prostate cancer,
prostate specific antigen (PSA) > 4 ng/mL), malignancy suspect
prostate by digital rectal examination (ALT) > 1.5 upper limit
of normal, erythrocyte volume fraction (EVF) > 50%, breast cancer
- Symptomatic obstructive sleep apnoea syndrome
- Heart failure > New York Heart Association class II
- Uncontrolled hypertension: (Systolic blood pressure > 160 mmHg
despite antihypertensive treatment, measured at two separate
occasions)
- Inability to understand information about the trial
- Participation in any other clinical trial
- Allergy for the active substance or additives in Tostran or placebo.
- Known diabetes mellitus, or diabetes mellitus detected at screening
or at baseline
- Paternity wish at the time of inclusiona
aIf there is any doubt about paternity wish at the time of inclusion, the study
subject should give a semen sample for analysis. If the semen sample shows
any viable sperm cells, the study subject will be excluded
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by a web-based randomization tool (http://www.rando
mization.com). Each subject will be assigned a specific
and unique randomization number. The randomization
code will be broken for a subject if a suspected adverse
event is judged by the investigators, as serious as it will
influence future treatment. The randomization code can
be broken at any time during the study period.
Blinding
Study participants and primary investigators are blinded.
An unblinded investigator will evaluate safety issues.
Intervention
If a subject meets the inclusion criteria, reviewed at the
screening and after the baseline investigations,
randomization will take place and the study participant
will be allocated to treatment with testosterone replace-
ment therapy or placebo. He will initiate treatment the
following day in the morning.
Study arm 1: Testosterone (Tostran 2% gel).
Study participants allocated to active treatment will re-
ceive 12 months daily treatment with Tostran 2% applied
transdermally. Dose adjustment will take place three
times during the initial 8 weeks to a maximal daily dose
of 40 mg (four depressions of the piston) (Table 2).
Study arm 2: Placebo.
Study participants allocated to placebo will receive
12 months daily treatment with placebo. Identical dose
adjustment will take place during the initial 8 weeks to
four depressions of the piston (Table 2).
The summary of product characteristics of Tostran 2%
can be seen at (http://www.medicines.org.uk/emc/medi-
cine/19702). Placebo contains the same substances as
Tostran 2% except for testosterone.
Tostran 2% and placebo will be supplied in an identi-
cal container labelled with a unique number. Each
container has a piston and a depression of the piston
delivers 0.5 g of gel which is equivalent to 10 mg of
testosterone in the intervention group.
Dose modifications
Dose adjustment during the initial 8 weeks and criteria
for dose modifications due to safety issues are shown in
Table 2. If dose modification due to safety issues is
needed, a study participant treated with placebo of the
same age or age closest to the study participant who
should be dose adjusted will be chosen for identical dose
modification to keep the double-blinded study design. If
more than one placebo-treated patient is at the same
age, the subject with a BMI closest to the study partici-
pant who should be dose-adjusted will be chosen for
identical dose modification.
Fig. 1 Study flow diagram
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Planned inclusion
It is estimated that 70 study participants will be included
by the end of 2018.
Measurements
The schedule for data assessment is presented in Table 3
and the study endpoints are presented in Table 4.
A human chorionic gonadotropin (hCG) stimulation
test will be done at the screening visit in order to evalu-
ate the residual capacity of the remaining testicle in the
included study participants: After blood sampling, where
serum testosterone is analysed, 5000 IU of hCG is
injected intramuscularly. Blood samples are drawn 72 h
after the administration of hCG for evaluation of serum
testosterone.
Study endpoints will be evaluated at baseline (before
randomization), 26 weeks post-randomization, 52 weeks
post-randomization (last dose) and 64 weeks post-
randomization (12 weeks after last dose). Participants will
arrive at the hospital after an overnight fast (minimum
8 h) at visits where study endpoints will be evaluated.
Primary outcome
The primary endpoint is insulin sensitivity expressed
as the 2 h change in blood glucose (Δ2 h glucose) eval-
uated by oral glucose tolerance test: Fasting blood
samples will be drawn where plasma glucose and insu-
lin are analysed. Afterwards, at time zero, 75 g glucose
will be administered orally after being dissolved in
250–300 ml water. Plasma glucose and insulin will be
analysed again after 2 h.
Secondary outcomes
Evaluation of each component of metabolic syndrome
(waist circumference, blood pressure, fasting plasma glu-
cose, plasma HDL-cholesterol and plasma triglycerides)
as well as presence of metabolic syndrome (≥3 compo-
nents) will be assessed according to the International
Diabetes Federation criteria [23]. Waist circumference
and hip circumference will be measured according to
guidelines from World Health Organization [24] and
blood pressure will be determined twice with an automatic
device after 5 min rest.
Table 2 Dose adjustments and dose modifications due to safety issues
Dose adjustment Dose modifications Follow-up
Starting dose: 10 mg daily
(one depression of the piston)
Week 2: 20 mg daily
(two depressions of the piston)
Week 4: 30 mg daily
(three depressions of the piston)
Week 8: 40 mg daily
(four depressions of the piston)
52 weeks: End of treatment
Safety issues
Increase in free testosterone to >3 SD
above the age-adjusted mean
Dose adjustment to previous treatment step Measurement of free testosterone and LH after
14 days and dose adjustment accordingly
Decrease in LH to < −2 SD below the
age-adjusted mean
Dose adjustment to previous treatment step Measurement of free testosterone and LH after
14 days and dose adjustment accordingly
Increase in EVF to >52% Dose adjustment to previous treatment step Measurement of EVF after 14 days and dose
adjustment accordingly
Plasma PSA > 4 ng/mL at any visit. A PSA
increase of >1 ng/mL at visit 7 or visit 8,
using plasma PSA at visit 6 as baseline
Referral for urological consultation According to urological consultation: Stop
treatment if increased risk of prostate cancer.
Continue treatment at the same treatment step
if there is no increased risk of prostate cancer
An increase in systolic blood pressure
> 20 mmHg confirmed at two separate
measurements despite antihypertensive
therapy, if not due to free testosterone
being >3 SD from the age-adjusted mean
Stop treatment Measurement of blood pressure after 14 days.
If still elevated referral to general practitioner
ALT increase >1.5 upper reference level Stop treatment Measurement of ALT after 14 days. If
still elevated referral for hepatological
consultation
Any other exclusion criteria becoming
apparent during treatment
Stop treatment
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Plasma samples for analysis of inflammatory markers:
tumor necrotic factor-alpha (TNF-alpha), interleukine (IL)-
1β, IL-6 and IL-10 as well as adipocytokines (adiponectin
and leptin) will be processed and stored at −80 C° for batch
analysis after completion of the study. Inflammatory
markers will be analysed by MesoScaleDiscovery multiplex
(MesoScaleDiscovery, USA) while leptin will be analysed by
immunoassay and adiponectin by radioimmunoassay.
Total plasma cholesterol, HDL-cholesterol, LDL-
cholesterol, plasma glucose, haemoglobin A1c and plasma
insulin will be measured using standard laboratory proce-
dures. Homeostasis Model Assessment index will be
calculated as described in [25].
Serum total testosterone and free testosterone will be
analysed by liquid chromatography–mass spectrometry
and LH will be analysed by time-resolved immunofluoro-
metric assay (Delfia; Perkin Elmer, Turku, Finland),
Body composition and bone mineral density will be
assessed by whole body Dual-energy X-ray absorpti-
ometry (DXA-scan) performed on a Lunar Prodigy
Advance Scanner (GE Healthcare, Madison, WI; soft-
ware package Encore v. 16). Whole body bone mineral
density (BMD) will be determined, as well as BMD of
the lumbar spine and proximal femoral bone. Lean body
mass, whole body fat percent, and visceral fat mass will
be determined.
Anogenital distance will be measured in supine position
with the legs abducted allowing the soles of the feet to
meet as described in [26]. The anogenital distance will be
measured at baseline and 52 months post-randomization
using a digital caliper.
Patient reported outcomes will be assessed by standard-
ized questionnaires: Quality of life (EORTC QLQ-30) [27],
fatigue (Multiple Fatigue Inventory) [28], symptoms of
testosterone deficiency and erectile dysfunction (Inter-
national Index of Erectile Dysfunction) (IIEF-15) [29] and
depression and anxiety (Hospital Anxiety and Depression
Scale) (HADS) [30].
EORTC QLQ-30 consists of nine symptom scales, five
function scales, and a global health/quality of life scale.
A high score on the symptom scales indicates a high
symptom burden while a high score on the function
scales and global function scale indicates lower symptom
burden. MFI-20 is covering five domains of fatigue: gen-
eral fatigue, physical fatigue, reduced activity, reduced
motivation and mental fatigue. A higher score on each
Table 4 Study Endpoints
Systemic effects
- Glucose metabolism (fasting glucose, 2 h glucose, insulin,
hemoglobin a1c, HOMA-index)
- Cholesterol (high density lipoprotein-cholesterol, low density
lipoprotein-cholesterol, total cholesterol)
- Inflammatory markers (interleukin 1-β, interleukin-6, interleukin-8,
tumour necrotic factor-alpha)
- Adipocytokines (adiponectin, leptin)
- Reproductive hormones (total testosterone, free testosterone,
luteinizing hormone)
Body composition and bone mineral density
- Whole body bone mineral density, whole body t-score, t-score of
the lumbar spine and proximal femoral bone
- Lean body mass
- Whole body fat percent (Z-score)




- Body mass index
- Anogenital distance
Patient reported outcomes
- Health related quality of Life (EORTC QLQ-C30)
- Anxiety and Depression: (Hospital Depression and Anxiety Scale)
- Fatigue: (Multiple Fatigue Inventory-20)
- Symptoms of testosterone deficiency and erectile dysfunction:
(International Index of Erectile Function-15)
Abbreviations: HOMA-index Homeostasis model assessment index, EORTC QLQ-
C30 European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire
Table 3 Data Assessment Schedule















Blood pressure x x x x x x x x
Blood samples x x x x x x x x
Waist circumference x x x x
DXA scan x x x x
Oral glucose tolerance test x x x x
Questionnaires x x x x
Anogenital distance x x
Randomization x
On treatment x x x x x x
Dose adjustment x x x
Evaluation of side effects x x x x x x x
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of the five scales indicates more fatigue. HADS consists
of two subscales covering anxiety and depression. A
higher score on each scale indicates higher symptom
burden. IIEF-15 examines the five main domains of male
sexual function: Erectile function, orgasmic function,
sexual desire, overall satisfaction and intercourse satis-
faction. A lower score indicates higher symptom burden.
Additionally, study participants will be asked about
medication, tobacco consumption, alcohol consumption
and level of physical activity.
Adverse events
Presence of side effects according to common toxicity
criteria version 4.0 (https://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf ) will
be evaluated at each visit and documented in case report
forms.
Sample size
It is expected that 30 study participants in each arm will
complete the study to week 52. A power calculation has
been conducted and with 30 study participants in each
arm, there is 80% power to show a 0.5 mmol difference
in Δ2 h glucose between baseline and 52 weeks between
the two arms. The significance level is set at 5%.
Analytic plan
Changes in continuous outcomes between baseline and
52 weeks will be compared between the investigational
group and placebo group with independent samples t-test.
Changes in prevalence of metabolic syndrome compo-
nents and metabolic syndrome between baseline and
52 weeks will be compared with chi-square test. Changes
in patient reported outcomes and adverse events be-
tween baseline and 52 weeks will be compared with
Mann–Whitney U-test. As an additional analysis out-
comes in the intervention arm will be compared with
independent samples t-test and chi-square test between
study participants who had an adequate response to the
hCG stimulation test performed at the screening visit
and those who had and inadequate response.
Discussion
Testosterone substitution is currently advocated in men
with evident biochemical testosterone deficiency mea-
sured on >1 occasion in concordance with clinical signs
and symptoms of testosterone deficiency in the general
population [31]. Mild Leydig cell insufficiency is a com-
mon condition in testicular cancer survivors, and it has
not been clarified whether testosterone substitution is of
potential benefit in this population. The results of the
present study might have the potential to change the
clinical handling of testicular cancer survivors with mild
Leydig cell insufficiency in order to decrease the long-
term risk of cardiovascular disease.
Recruitment of study participants began in November
2016. By the end of January 2017, approximately 60 po-
tential study participants have received information
about the study of which 22 have signed informed
consent and been through screening examinations. The
most common reason for not wanting to participate in
the study after having received information has been
that potential study participants found the study too
time consuming. Fear of adverse effects to testosterone
treatment has been the second most common reason for
non-paticipation.
Ten of the 22 screened study participants have so far
been randomized, four are in line for randomization
while there have been eight screening failures.
As testosterone and LH show considerable day –to-
day variation [32] screening failures would be expected.
It should, however, be emphasized that all study partici-
pants who are undergoing screening examinations have
experienced elevated serum LH levels in combination
with borderline low serum testosterone at a previous
point in time. Accordingly, inclusion in this study is
based on at least two measurements of elevated LH and
borderline low testosterone levels.
In conclusion, the results of this study will provide
evidence for the clinical handling of TC survivors with
mild Leydig cell insufficiency and potentially improve
morbidity and quality of life in this subgroup of cancer
survivors.
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